Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ross C Donehower

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancerPhilip A Philip, Michelle R Mahoney, Cristine Allmer, et al.
Cancer Chemotherapy and Pharmacology|April 2, 2008
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumorsWells A Messersmith, Antonio Jimeno, David Ettinger, et al.
European Journal of Cancer (Oxford, England : 1990)|November 7, 2006
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumoursWells A Messersmith, Michelle A Rudek, Sharyn D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studiesAlex Sparreboom, Antonio C Wolff, Jaap Verweij, et al.
Investigational New Drugs|April 12, 2012
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancerGlen J Weiss, Ross C Donehower, Tara Iyengar, et al.
Cancer Chemotherapy and Pharmacology|April 13, 2007
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumorsAntonio Jimeno, Michelle A Rudek, Thomas Purcell, et al.
Cancer|October 10, 2013
Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastasesGeorgios Karagkounis, Michael S Torbenson, Hubert D Daniel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicitiesWells A Messersmith, Daniel A Laheru, Neil N Senzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumorsWells A Messersmith, Sharyn D Baker, Lance Lassiter, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 9, 2013
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancerDung T Le, Eric Lutz, Jennifer N Uram, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancerPhilip A Philip, Michelle R Mahoney, Cristine Allmer, et al.
Cancer Chemotherapy and Pharmacology|April 2, 2008
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumorsWells A Messersmith, Antonio Jimeno, David Ettinger, et al.
European Journal of Cancer (Oxford, England : 1990)|November 7, 2006
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumoursWells A Messersmith, Michelle A Rudek, Sharyn D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studiesAlex Sparreboom, Antonio C Wolff, Jaap Verweij, et al.
Investigational New Drugs|April 12, 2012
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancerGlen J Weiss, Ross C Donehower, Tara Iyengar, et al.
Cancer Chemotherapy and Pharmacology|April 13, 2007
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumorsAntonio Jimeno, Michelle A Rudek, Thomas Purcell, et al.
Cancer|October 10, 2013
Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastasesGeorgios Karagkounis, Michael S Torbenson, Hubert D Daniel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicitiesWells A Messersmith, Daniel A Laheru, Neil N Senzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumorsWells A Messersmith, Sharyn D Baker, Lance Lassiter, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 9, 2013
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancerDung T Le, Eric Lutz, Jennifer N Uram, et al.
Pageof 5